Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06041594

Treating Pulmonary Embolism With Laguna Thrombectomy System (TRUST)

This is a prospective, multi-center, pivotal study to demonstrate the safety and effectiveness of the Laguna Thrombectomy System for the treatment of pulmonary embolism. The Laguna Thrombectomy System is an investigational device which consists of the Laguna Clot Retriever™ System and the Malibu Aspiration Catheter™ System. These devices are manufactured by Innova Vascular, Inc.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–85 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Ankara Bilkent City Hospital, Ankara, Turkey (Türkiye)

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • ≥ 18 years of age; < 85 years old
  • RV/LV ratio > 0.9 as determined by CTA
  • Systolic blood pressure > 90 mmHg
  • Heart rate ≤ 120
  • Patient is deemed eligible for procedure by the interventional investigator
  • CTA evidence of proximal PE (filling defect in at least one main or lobar pulmonary artery)
  • PE Symptom duration ≤ 14 days

Exclusion criteria

  • Systolic pulmonary artery pressure > 70 mmHg on initial invasive hemodynamic assessments
  • Life expectancy of < 90 days in the opinion of investigator at the time of enrollment
  • Subject pregnant or breast feeding
  • Current participation in another drug or medical device treatment study
  • In active chemotherapy or radiation treatment for a malignancy during the course of the study
  • Any intravascular administration of a fibrinolytic agent (such as Alteplase or Tenecteplase) within the last 30 days
  • Presence of recently placed (<8 weeks) intracardiac devices (such as pacemaker leads) in the right ventricle or right atrium
  • History of prior PE within the past 90 days
  • FiO2 Requirement: > 40% (6 LPM) to keep oxygen saturation > 90%
  • Hematocrit: < 28%
  • Platelets: < 100,000/microliter
  • Serum Creatinine: > 2 mg/dL
  • International Normalized Ratio (INR): > 3
  • Major Trauma Injury Severity Score (ISS): > 15
  • Cardiovascular or pulmonary surgery within the last 7 days
  • Known bleeding diathesis or coagulation disorder that cannot be managed with anti-coagulation
  • History of known severe or chronic pulmonary arterial hypertension
  • History or chronic left heart disease with left ventricular ejection fraction < 30%
  • History of underlying lung disease that is oxygen dependent
  • History of chest irradiation
  • Known anaphylactic reaction to radiographic contrast agents that cannot be pretreated
  • Any absolute contraindication to systemic or therapeutic dosage of heparin or anticoagulants
  • Imaging or other evidence that suggests, in the opinion of the investigator, the subject is not appropriate for mechanical thrombectomy intervention (e.g., inability to navigate to target location, predominantly chronic clot or non-clot embolus)
  • Known presence of clot in transit within right atrium or ventricle

Treatment and study plan

Laguna Thrombectomy System

Device

Removal of clot using the Laguna Thrombectomy System to treat Pulmonary Embolism

Primary outcomes

  1. A composite of the following major adverse events occurring within 48 (± 8) hours post-procedure:

    Time frame: within 48 (± 8) hours post-procedure

    • Device-related death within 48 (± 8) hours post-procedure
    • Major bleeding as defined by GUSTO (moderate or severe) within 48 (± 8) hours post-procedure.
    • The following treatment-related adverse events within 48 (± 8) hours post-procedure:
    • Cardio-respiratory deterioration,
    • Pulmonary vascular injury, and/or
    • Cardiac injury
  2. Reduction in RV/LV ratio from baseline to 48 (± 8) hours (or at discharge, whichever occurs first) as assessed by Computed Tomography Angiography (CTA)

    Time frame: from baseline to 48 (± 8) hours (or at discharge, whichever occurs first)

Study contacts

Contact information is provided by the study sponsor or research team.

Sanjay Shrivastava, Ph.D.

CONTACT

[email protected]

949-295-6040

Sponsors and collaborators

Lead sponsor

Innova Vascular, Inc.

Industry

Registry information

Acronym: TRUST

Important dates

Study start
2024
Primary completion
2026
Study completion
2026
First posted
Sep 18, 2023
Registry last updated
Jul 17, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.